CN101450075A - 羟乙基淀粉130/0.4氯化钠注射液及制备方法、用途 - Google Patents
羟乙基淀粉130/0.4氯化钠注射液及制备方法、用途 Download PDFInfo
- Publication number
- CN101450075A CN101450075A CNA2007100506564A CN200710050656A CN101450075A CN 101450075 A CN101450075 A CN 101450075A CN A2007100506564 A CNA2007100506564 A CN A2007100506564A CN 200710050656 A CN200710050656 A CN 200710050656A CN 101450075 A CN101450075 A CN 101450075A
- Authority
- CN
- China
- Prior art keywords
- injection
- hetastarch
- sodium chloride
- molecular weight
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008354 sodium chloride injection Substances 0.000 title claims abstract description 13
- 229920001612 Hydroxyethyl starch Polymers 0.000 title claims description 58
- 238000002360 preparation method Methods 0.000 title claims description 13
- 229940050526 hydroxyethylstarch Drugs 0.000 title description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 36
- 238000002347 injection Methods 0.000 claims abstract description 24
- 239000007924 injection Substances 0.000 claims abstract description 24
- 239000011780 sodium chloride Substances 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 7
- 206010021137 Hypovolaemia Diseases 0.000 claims abstract description 5
- 229940027278 hetastarch Drugs 0.000 claims description 52
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000008215 water for injection Substances 0.000 claims description 7
- 239000003058 plasma substitute Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 239000003610 charcoal Substances 0.000 claims description 4
- 238000009413 insulation Methods 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 229920002472 Starch Polymers 0.000 abstract description 5
- 238000009826 distribution Methods 0.000 abstract description 5
- 239000008107 starch Substances 0.000 abstract description 5
- 235000019698 starch Nutrition 0.000 abstract description 5
- 230000001154 acute effect Effects 0.000 abstract description 4
- -1 ethoxyl Chemical group 0.000 abstract description 4
- 206010059484 Haemodilution Diseases 0.000 abstract description 3
- 239000012530 fluid Substances 0.000 abstract description 3
- 238000001990 intravenous administration Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 230000000287 tissue oxygenation Effects 0.000 abstract description 2
- 238000006073 displacement reaction Methods 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000006213 oxygenation reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 24
- 229960002668 sodium chloride Drugs 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 14
- 230000000694 effects Effects 0.000 description 11
- 238000001802 infusion Methods 0.000 description 11
- 230000001954 sterilising effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000084 colloidal system Substances 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000010494 opalescence Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- YKIOKAURTKXMSB-UHFFFAOYSA-N adams's catalyst Chemical compound O=[Pt]=O YKIOKAURTKXMSB-UHFFFAOYSA-N 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
活性炭用量(g/ml) | 0 | 0.1% | 0.2% | 0.4% |
澄明度 | 合格 | 合格 | 合格 | 合格 |
羟乙基淀粉含量(%) | 99.85 | 99.83 | 99.78 | 99.72 |
氯化钠含量(%) | 99.76 | 99.74 | 99.71 | 99.63 |
名称 | 外观性状 | pH值 | Mw | 羟乙基淀粉含量(%) | 氯化钠含量(%) | 无菌检查 |
灭菌前 | 无色稍带粘性的澄明液体,显轻微的乳光,味咸。 | 5.67 | 148392 | 99.85 | 99.76 | 不合格 |
灭菌30分钟 | 无色稍带粘性的澄明液体,显轻微的乳光,味咸。 | 5.71 | 143382 | 99.79 | 99.73 | 合格 |
循环次数 | 澄清度 | 澄明度 | 羟乙基淀粉含量(%) | 氯化钠含量(%) | Mw | 10%大分子重均分子量 | 90%小分子重均分子量 |
0 | 澄清 | 合格 | 99.85 | 99.76 | 145392 | 297832 | 73673 |
1 | 澄清 | 合格 | 99.81 | 99.68 | 142981 | 293223 | 71298 |
2 | 浅于2号浊度液 | 不合格 | 99.75 | 99.72 | 143662 | 292367 | 70233 |
3 | 浅于3号浊度液 | 不合格 | 99.90 | 99.75 | 146321 | 301672 | 78723 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100506564A CN101450075B (zh) | 2007-11-30 | 2007-11-30 | 羟乙基淀粉130/0.4氯化钠注射液及制备方法、用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100506564A CN101450075B (zh) | 2007-11-30 | 2007-11-30 | 羟乙基淀粉130/0.4氯化钠注射液及制备方法、用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101450075A true CN101450075A (zh) | 2009-06-10 |
CN101450075B CN101450075B (zh) | 2012-01-18 |
Family
ID=40732673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100506564A Expired - Fee Related CN101450075B (zh) | 2007-11-30 | 2007-11-30 | 羟乙基淀粉130/0.4氯化钠注射液及制备方法、用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101450075B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102276742A (zh) * | 2011-08-09 | 2011-12-14 | 武汉华科大生命科技有限公司 | 一种中分子量羟乙基淀粉的洁净生产方法 |
CN102327209A (zh) * | 2011-09-30 | 2012-01-25 | 南京正大天晴制药有限公司 | 羟乙基淀粉130/0.4氯化钠注射液的制备方法 |
CN102397290A (zh) * | 2011-06-27 | 2012-04-04 | 辽宁海神联盛制药有限公司 | 一种羟乙基淀粉注射液及其制备方法 |
CN102697717A (zh) * | 2012-06-27 | 2012-10-03 | 青岛华仁药业股份有限公司 | 一种羟乙基淀粉氯化钠注射液及其制备方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1813795A (zh) * | 2005-12-06 | 2006-08-09 | 山东诚创医药技术开发有限公司 | 一种药物组合物 |
CN101081229B (zh) * | 2006-05-30 | 2011-01-26 | 四川科伦药业股份有限公司 | 以羟乙基淀粉作为血浆扩容剂的代血浆注射液 |
CN101032512B (zh) * | 2006-07-05 | 2010-05-12 | 北京费森尤斯卡比医药有限公司 | 一种用于扩充血容量的药物组合物及其制备方法 |
-
2007
- 2007-11-30 CN CN2007100506564A patent/CN101450075B/zh not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102397290A (zh) * | 2011-06-27 | 2012-04-04 | 辽宁海神联盛制药有限公司 | 一种羟乙基淀粉注射液及其制备方法 |
CN102397290B (zh) * | 2011-06-27 | 2013-06-05 | 辽宁海神联盛制药有限公司 | 一种羟乙基淀粉注射液及其制备方法 |
CN102276742A (zh) * | 2011-08-09 | 2011-12-14 | 武汉华科大生命科技有限公司 | 一种中分子量羟乙基淀粉的洁净生产方法 |
CN102327209A (zh) * | 2011-09-30 | 2012-01-25 | 南京正大天晴制药有限公司 | 羟乙基淀粉130/0.4氯化钠注射液的制备方法 |
CN102697717A (zh) * | 2012-06-27 | 2012-10-03 | 青岛华仁药业股份有限公司 | 一种羟乙基淀粉氯化钠注射液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101450075B (zh) | 2012-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101450075B (zh) | 羟乙基淀粉130/0.4氯化钠注射液及制备方法、用途 | |
CN102626409B (zh) | 一种含18种氨基酸的药物组合物 | |
CN112426405A (zh) | 预防及控制近视发展的药物组合物、滴眼液及其制备方法与应用 | |
CN103040740A (zh) | 一种奥硝唑注射液及制备工艺 | |
WO2022222630A1 (zh) | 一种复方电解质注射液及其制备方法 | |
CN102579329B (zh) | 一种乳酸米力农注射液及其制备方法 | |
CN104706655B (zh) | 注射用环磷腺苷葡胺粉针剂药物组合物和制法 | |
CN111494311A (zh) | 一种盐酸多巴胺注射液及其制备方法 | |
CN103381140A (zh) | 一种肌苷与氯化钠组合物及其制备方法 | |
CN101507747B (zh) | 黄芪总皂苷氯化钠注射液的制备方法 | |
CN102525893B (zh) | 盐酸去氧肾上腺素注射液及其制剂工艺 | |
CN102525909B (zh) | 盐酸戊乙奎醚注射液的制备方法 | |
CN104434788B (zh) | 一种阿替洛尔注射液的制备方法 | |
CN114209647A (zh) | 一种羟乙基淀粉注射液及其制备方法 | |
CN101822690B (zh) | 一种右旋糖酐40与乳酸钠林格氏液组合物及制备方法 | |
CN102525910B (zh) | 盐酸戊乙奎醚注射液的制备工艺 | |
CN103284943B (zh) | 一种盐酸戊乙奎醚注射液的制备方法 | |
CN102000106B (zh) | 一种防治有机磷农药所致血管损伤的药物组合物及其制备方法 | |
CN112516125B (zh) | 酪氨酸在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用 | |
CN100563664C (zh) | 一种液体药剂及其制备方法和用途 | |
CN1194831A (zh) | 利巴韦林大输液系列制剂 | |
CN101889979A (zh) | 一种犬用伊曲康唑注射液及其制备方法 | |
CN101229185B (zh) | 一种治疗重症疾病用的药物组合物 | |
CN117257731A (zh) | 己酮可可碱注射液 | |
CN101152204A (zh) | 氯法拉滨的静脉给药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 611231 sheep in Chongzhou city Zhenhe Hing Road No. 606 Ma Patentee after: CHENGDU ZHENGKANG PHARMACEUTICAL Co.,Ltd. Address before: Chongzhou City, Sichuan Province, 611231 sheep and horse Zhenhe Hing Road No. 606 Patentee before: CHENGDU ZHENGKANG PHARMACEUTICAL Co.,Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: Chongzhou City, Sichuan Province, 611200 sheep and horse Zhenhe Hing Road No. 606 Patentee after: CHENGDU ZHENGKANG PHARMACEUTICAL Co.,Ltd. Address before: Chongzhou City, Yang Ma Zhenhe Hing Road No. 606 Patentee before: CHENGDU ZHENGKANG PHARMACEUTICAL Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: Chongzhou City, Sichuan Province, 611231 sheep and horse Zhenhe Hing Road No. 606 Patentee after: CHENGDU ZHENGKANG PHARMACEUTICAL Co.,Ltd. Address before: Chongzhou City, Sichuan Province, 611200 sheep and horse Zhenhe Hing Road No. 606 Patentee before: CHENGDU ZHENGKANG PHARMACEUTICAL Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120118 Termination date: 20211130 |